Table 1.
Baseline demographics of the enrolled and randomized population.
| ChAdOx1-S full dose |
ChAdOx1-S half dose |
BNT162b2 half dose |
|
|---|---|---|---|
| N = | 232 | 236 | 234 |
| Sex, n (%) | |||
| Female | 105 (45.3) | 106 (44.9) | 109 (46.6) |
| Male | 127 (54.7) | 130 (55.1) | 125 (53.4) |
| Age, years | |||
| Median (IQR) | 29.7 (24.0, 38.4) | 28.8 (23.6, 38.2) | 28.8 (23.9, 36.8) |
| Ethnicity, n (%) | |||
| White | 57 (24.6) | 60 (25.4) | 53 (22.6) |
| Black | 60 (25.9) | 58 (24.6) | 58 (24.8) |
| Mixed | 62 (26.7) | 66 (28.0) | 66 (28.2) |
| Asian | 1 (0.4) | 0 | 1 (0.4) |
| Indigenous | 1 (0.4) | 1 (0.4) | 3 (1.3) |
| Other | 41 (17.7) | 36 (15.3) | 43 (18.4) |
| Unknown/Refused to answer | 10 (4.3) | 15 (6.4) | 10 (4.3) |
| Body Mass Index, kg/m2 | |||
| Median (IQR) | 26.1 (22.6, 29.7) | 26.3 (22.6, 31.2) | 26.3 (23.1, 29.7) |
| Interval between 1st and 2nd COVID-19 vaccinations, days | |||
| Median (IQR) | 28 (27, 30) | 28 (28, 30) | 28 (27, 31) |
| Interval between 2nd COVID-19 vaccination and randomization, days | |||
| Median (IQR) | 215 (178, 261) | 215 (176, 259) | 219 (178, 253) |